Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

Verastem Oncology (VSTM) announced that it has dosed the first patient in a phase I/II study evaluating its KRAS G12D inhibitor, GFH375/VS-7375, for treating KRAS G12D mutant solid tumors. Verastem's collaboration partner GenFleet Therapeutics is conducting the study in China. We note that after evaluating the initial dose escalation data from the above mentioned phase I study in China, VSTM plans to expedite the development path ahead for GFH375/VS-7375 in the United States. In May 2024, VSTM initiated the ...